These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 15290879)

  • 1. Your money or their life. Drug to combat blood pressure may come at a price, but the wider health benefits should not be underestimated, says Nick Summerton.
    Summerton N
    Health Serv J; 2004 Jul; 114(5914):24-5. PubMed ID: 15290879
    [TBL] [Abstract][Full Text] [Related]  

  • 2. How willing are the public to pay for anti-hypertensive drugs for primary prevention of cardiovascular disease: a survey in a Chinese city.
    Tang JL; Wang WZ; An JG; Hu YH; Cheng SH; Griffiths S
    Int J Epidemiol; 2010 Feb; 39(1):244-54. PubMed ID: 19491141
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treating pulmonary arterial hypertension: is it worth it?
    Gibbs JS
    Heart; 2010 Oct; 96(20):1607-8. PubMed ID: 20937746
    [No Abstract]   [Full Text] [Related]  

  • 4. Benefits and cost of antihypertensive treatment in incipient and overt diabetic nephropathy.
    Parving HH
    J Hypertens Suppl; 1998 Jan; 16(1):S99-101. PubMed ID: 9534107
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The financial cost of optimising blood pressure control.
    Shiner T; Simons L; Parkinson H; Khanbhai A; Karthikeyan VJ; Nandhara G; Beevers DG
    J Hum Hypertens; 2005 Jan; 19(1):83-4. PubMed ID: 15372065
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differences in medical expenditure according to drug prices.
    Ueshima H
    Hypertens Res; 2006 May; 29(5):301-2. PubMed ID: 16832148
    [No Abstract]   [Full Text] [Related]  

  • 7. Guidelines for the management of hypertension at primary health care level. Hypertension Society of Southern Africa, endorsed by the Medical Association of South Africa and the Medical Research Council.
    S Afr Med J; 1995 Dec; 85(12 Pt 2):1321-5. PubMed ID: 8600604
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pricing and costs of drugs in the United States and Sweden: a comparison based on drug acquisition costs at the patient outcome level.
    Melander A; Nilsson JL
    J Ambul Care Manage; 2004; 27(2):115-9. PubMed ID: 15069988
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gap between evidence and physicians' knowledge and practice regarding hypertension and its drug treatment: a survey in a Chinese city.
    Wang WZ; Tang JL; Hu YH; An JG; Wang YL; Ren ZH; Zhang H; Griffiths S
    Chin Med J (Engl); 2011 Apr; 124(8):1235-41. PubMed ID: 21543003
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improving cost-effectiveness of hypertension management at a community health centre.
    Edwards PR; Lunt DW; Fehrsen GS; Lombard CJ; Steyn K
    S Afr Med J; 1998 May; 88(5):549-54. PubMed ID: 9638122
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The cost-effectiveness of implementing a new guideline for cardiovascular risk management in primary care in the Netherlands.
    Kok L; Engelfriet P; Jacobs-van der Bruggen MA; Hoogenveen RT; Boshuizen HC; Verschuren MW
    Eur J Cardiovasc Prev Rehabil; 2009 Jun; 16(3):371-6. PubMed ID: 19305351
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rationale for the hypertension guidelines for primary care in South Africa.
    Opie LH; Steyn K
    S Afr Med J; 1995 Dec; 85(12 Pt 2):1325-8, 1330-1, 1334-5 passim. PubMed ID: 8600605
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of hypertension therapy according to 2014 guidelines.
    Moran AE; Odden MC; Thanataveerat A; Tzong KY; Rasmussen PW; Guzman D; Williams L; Bibbins-Domingo K; Coxson PG; Goldman L
    N Engl J Med; 2015 Jan; 372(5):447-55. PubMed ID: 25629742
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The cost-effectiveness of drug treatments for primary prevention of cardiovascular disease: a modelling study.
    Marshall T
    Eur J Cardiovasc Prev Rehabil; 2006 Aug; 13(4):523-8. PubMed ID: 16874140
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Results of a Markov model analysis to assess the cost-effectiveness of a single tablet of fixed-dose amlodipine and atorvastatin for the primary prevention of cardiovascular disease in Korea.
    Liew D; Park HJ; Ko SK
    Clin Ther; 2009 Oct; 31(10):2189-203; discussion 2150-1. PubMed ID: 19922890
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost effectiveness analysis of improved blood pressure control in hypertensive patients with type 2 diabetes: UKPDS 40. UK Prospective Diabetes Study Group.
    UK Prospective Diabetes Study Group
    BMJ; 1998 Sep; 317(7160):720-6. PubMed ID: 9732339
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improving prescribing practices in primary care. A randomised trial and economic analysis of a multicomponent intervention showed small, but important, gains.
    Del Mar C
    PLoS Med; 2006 Jun; 3(6):e229. PubMed ID: 16729845
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapy in the elderly hypertensive.
    Meredith PA; Trenkwalder P
    J Renin Angiotensin Aldosterone Syst; 2002 Sep; 3 Suppl 1():S49-56. PubMed ID: 12428220
    [No Abstract]   [Full Text] [Related]  

  • 19. Evaluating national guidelines for prevention of cardiovascular disease in primary care.
    Marshall T
    J Eval Clin Pract; 2005 Oct; 11(5):452-61. PubMed ID: 16164586
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Investigation and treatment of primary hypertension].
    Lindstedt I; Nilsson PM
    Lakartidningen; 2008 Jul 23-Aug 5; 105(30-31):2107-12. PubMed ID: 18751450
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.